Scientists in Brazil are refining the design of CAR-engineered immune cells to make them more precise and powerful against cancer.

Since scientists first discovered that human immune cells could be modified to become cancer-fighting agents, they've been trying to engineer a cell that's effective against solid tumors, which ...

Many people’s brains deteriorate as they age, becoming riddled with malfunctioning proteins that result in cell death and the ...

Experts at Cincinnati Children's report proof-of-concept results that may sharply reduce the risk of a lethal side effect ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives.

The difficulty is that EBV lives latently in B cells in the blood at a frequency, in most immunocompetent individuals, of about 1 in 100,000 to 1 in a million. That level of infection is below the ...

Today, the American Diabetes Association(R) (ADA) announced the awardees of the 2026 Pathway to Stop Diabetes(R) (Pathway) Award grants. The seven new awards, totaling $11.3 million in strategic ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

In the rapidly moving field, questions remain regarding long-term safety, durability of remission, and the FDA’s approach to ...

Researchers from Tr1x Inc. presented the development of TRX-319, a novel allogeneic regulatory T-cell therapy designed for the treatment of autoimmune disorders.

A promising clinical trial underway at UCI Health is aimed at helping patients achieve long-term remission.